Aus Pubmed

Life (Basel). 2024 Oct 13;14(10):1297. doi: 10.3390/life14101297. ABSTRACT (1) Background: The purpose of this study is to compare the rate of COVID-19 vaccination among psoriasis patients internationally and to correlate it with their treatment regimens. (2) Methods: We conducted a cross-sectional study from January 2021 to October 2022 among adults in the United States (US), Chile, China, Switzerland, and Singapore using the Global Healthcare Study on Psoriasis survey. (3) Results: A total of

Life (Basel). 2024 Oct 6;14(10):1271. doi: 10.3390/life14101271. ABSTRACT Autofluorescence is a remarkable property of human skin. It can be excited by UV and observed in the dark using special detection systems. The method of fluorescence photography (FP) is an effective non-invasive tool for skin assessment. It involves image capturing by a camera the emission of light quanta from fluorophore molecules in the skin. It serves as a useful tool for cosmetic and skincare research, especially for t

Medicina (Kaunas). 2024 Oct 3;60(10):1619. doi: 10.3390/medicina60101619. ABSTRACT Psoriasis is a common chronic inflammatory skin disease, associated with significant morbidity and a considerable negative impact on the patients' quality of life. The complex pathogenesis of psoriasis is still incompletely understood. Genetic predisposition, environmental factors like smoking, alcohol consumption, psychological stress, consumption of certain drugs, and mechanical trauma, as well as specific immun

Pharmaceuticals (Basel). 2024 Oct 16;17(10):1378. doi: 10.3390/ph17101378. ABSTRACT (1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis. Our real-world-evidenc

Pharmaceuticals (Basel). 2024 Oct 16;17(10):1376. doi: 10.3390/ph17101376. ABSTRACT Background/Objectives: This study investigates the chemical composition, antioxidant, antibacterial, and hemolytic properties of ylang-ylang (Cananga odorata) essential oil, with a focus on its potential therapeutic applications for dermatological diseases and the importance of transforming such bioactive properties into a stable, safe, and effective formulation. Methods/Rsults: Essential oils were extracted from

Pharmaceutics. 2024 Oct 14;16(10):1329. doi: 10.3390/pharmaceutics16101329. ABSTRACT BACKGROUND: The treatment of psoriasis has made considerable progress with biologicals, including tumor necrosis factor inhibitors, and recently, monoclonal antibodies inhibiting directly interleukin (IL) 17, IL-23, or both IL-12/23. Newer biologicals are directed to the interleukin pathway and appear to improve complete or near-complete clearance. The newer biologicals have also been shown to have an excellent

Pharmaceutics. 2024 Oct 4;16(10):1295. doi: 10.3390/pharmaceutics16101295. ABSTRACT BACKGROUND/OBJECTIVES: Implementing model-informed precision dosing (MIPD) strategies guided by population pharmacokinetic/pharmacodynamic (PK/PD) models could enhance the management of inflammatory diseases such as psoriasis. However, the extent of individual experimental data gathered during MIPD significantly influences the uncertainty in estimating individual PK/PD parameters, affecting clinical dose selectio

Pharmaceutics. 2024 Sep 30;16(10):1287. doi: 10.3390/pharmaceutics16101287. ABSTRACT BACKGROUND: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects. OBJECTIVES: This study focuses on developing a lipid-based topical formulation of baricitinib (BCT-OS) for treating psoriasis. METHODS: The optimized formulatio

Microorganisms. 2024 Oct 3;12(10):2010. doi: 10.3390/microorganisms12102010. ABSTRACT The skin plays a crucial role in maintaining homeostasis and protecting against external aggressors. Recent research has highlighted the potential of probiotics and postbiotics in dermatological treatments and skincare. These beneficial microorganisms interact with the skin microbiota, modulate the immune response, and enhance the skin barrier, offering a promising therapeutic avenue for various skin conditions

Arch Physiol Biochem. 2024 Oct 24:1-13. doi: 10.1080/13813455.2024.2407547. Online ahead of print. ABSTRACT CONTEXT: Insulin resistance and a disturbed lipid profile are common associations with type 2 diabetes mellitus (T2DM) and different skin diseases, particularly psoriasis (PsO). OBJECTIVES: We investigated potential therapeutic mechanisms of metformin in a murine animal model of psoriasiform lesions in T2DM. MATERIALS AND METHODS: Forty-two rats were randomly divided into control, PsO, and

J Eur Acad Dermatol Venereol. 2024 Oct 24. doi: 10.1111/jdv.20400. Online ahead of print. NO ABSTRACT PMID:39445679 | DOI:10.1111/jdv.20400 Den ganzen Artikel lesen

J Clin Aesthet Dermatol. 2024 Oct;17(10):18. NO ABSTRACT PMID:39445327 | PMC:PMC11495167 Den ganzen Artikel lesen

J Clin Aesthet Dermatol. 2024 Oct;17(10):19-22. ABSTRACT OBJECTIVE: We sought to correlate the time lag between psoriatic arthritis (PsA) symptom onset and diagnosis to the likelihood and severity of depression, social impairment, and disease impact on quality of life. METHODS: This cross-sectional study conducted by the National Psoriasis Foundation (NPF) surveyed individuals with PsA using patient-reported outcome measures. RESULTS: The analysis cohort comprised 2,196 patients with PsA. Likeli

J Clin Aesthet Dermatol. 2024 Oct;17(10):63-67. ABSTRACT OBJECTIVE: Tildrakizumab, an anti-interleukin-23 p19 monoclonal antibody, is approved for the treatment of adults with moderate-to-severe plaque psoriasis. Limited evidence is available regarding the effects of tildrakizumab on patient-reported symptoms and satisfaction. This report describes the secondary endpoints of patient-reported symptoms and treatment satisfaction over 64 weeks in patients with moderate-to-severe plaque psoriasis tr

Front Immunol. 2024 Oct 7;15:1435141. doi: 10.3389/fimmu.2024.1435141. eCollection 2024. ABSTRACT Recent studies have shown that local injection of secukinumab can achieve positive therapeutic effects when applied in the treatment of nail psoriasis. At present, there have been no other studies on the use of biological agents in the treatment of pediatric nail psoriasis. Three children were included in the study to evaluate the efficacy and safety of periungual injection and long-term injection o

Cureus. 2024 Sep 22;16(9):e69912. doi: 10.7759/cureus.69912. eCollection 2024 Sep. ABSTRACT Background Psoriasis is a persistent inflammatory condition of the skin marked by clearly demarcated red plaques adorned with silvery scales. It impacts individuals across different age ranges and presents with unique clinical, histological, and dermoscopic characteristics. This research seeks to offer an extensive assessment of the demographic, clinical, histological, and dermoscopic attributes of chroni

Int J Rheum Dis. 2024 Oct;27(10):e15390. doi: 10.1111/1756-185X.15390. ABSTRACT OBJECTIVES: To evaluate the risk of liver fibrosis and associated factors with the non-invasive fibrosis score-4 (FIB-4) index in patients with inflammatory arthritis using methotrexate (MTX). METHODS: Patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) who were followed up in the rheumatology outpatient clinic, who were on methotrexate only and for whom FIB-4 index was could be calculated at methot

Autoimmun Rev. 2024 Oct 21:103671. doi: 10.1016/j.autrev.2024.103671. Online ahead of print. ABSTRACT AIM: To produce a unique metric 'autoimmune disease (ADs)' based on various single autoimmune disorder and estimate its case number and age-standardized rate of incidence for each stage in life cycle of women from 1990 to 2019, and to further explore their temporal trends at global, regional, and national levels. METHODS: A comprehensive classification for life cycle of women was proposed. The e

Br J Dermatol. 2024 Oct 23:ljae402. doi: 10.1093/bjd/ljae402. Online ahead of print. ABSTRACT BACKGROUND: ABP 654 is a biosimilar to ustekinumab reference product (RP). ABP 654 has been shown to have an amino acid sequence identical to ustekinumab RP and they are similar in structure, purity, and potency as well as clinical pharmacokinetics and safety in healthy volunteers. OBJECTIVES: This randomized, double-blinded, active-controlled, single-transition, comparative clinical study (ClinicalTria

Sci Rep. 2024 Oct 22;14(1):24922. doi: 10.1038/s41598-024-75190-x. ABSTRACT The availability of a number of bDMARDs with different mechanism of action increases potential treatment pathways in psoriatic arthritis (PsA). In clinical practice, following the failure of one bDMARD, it is normal to consider which options are the best for switching strategy. In most cases this choice involves IL17i and TNFi. The main aim of this study was to compare the effectiveness of cycling (from TNFi to another T

RMD Open. 2024 Oct 22;10(4):e004699. doi: 10.1136/rmdopen-2024-004699. ABSTRACT OBJECTIVES: The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). METHODS: As part of a Design Thinking approach, six focus grou

RMD Open. 2024 Oct 22;10(4):e004457. doi: 10.1136/rmdopen-2024-004457. ABSTRACT OBJECTIVE: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Adding to studies focused on the role of T cells and macrophages, we sought to investigate the systemic activation of leukocytes in PsA. METHODS: We assessed the activation state of leukocyte populations, including polymorphonuclear neutrophils (PMNs) and monocyte/macrophages, in blood and synovial fluid (SF) by multicolour f

Br J Dermatol. 2024 Oct 22:ljae406. doi: 10.1093/bjd/ljae406. Online ahead of print. ABSTRACT BACKGROUND: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the United States, European Union, Japan, South Korea, China, and other countries for treatment of moderate-to-severe plaque psoriasis. OBJECTIVE: To evaluate the efficacy and safety of deucravacitinib in Asian patients with moderate to severe plaque psoriasis. METHODS: In the 52-week, blinded, phase

J Invest Dermatol. 2024 Oct 22:S0022-202X(24)02161-4. doi: 10.1016/j.jid.2024.09.012. Online ahead of print. ABSTRACT As medicine advances, cures are being found for diseases that were previously considered incurable, as is the case for some types of cancer. Traditionally, the term cure is reserved for resolution of disease, both at a clinical and a molecular level, which continues after cessation of treatment. Biologic therapies have revolutionized the definition of remission in severe psoriasi

J Dermatol. 2024 Oct 22. doi: 10.1111/1346-8138.17450. Online ahead of print. ABSTRACT Psoriasis is a skin disease with a complicated pathophysiology that includes an extensive inflammatory cytokine network. Nevertheless, the relationship between psoriasis severity, cytokine levels, and coronary artery atherosclerosis remains poorly understood. Our aim was to find serum markers as potential candidates for cardiovascular disease (CVD) risk monitoring in patients with psoriasis. Therefore, we exam